• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

婴幼儿哌拉西林-他唑巴坦给药策略的剂量-暴露模拟

Dose-Exposure Simulation for Piperacillin-Tazobactam Dosing Strategies in Infants and Young Children.

作者信息

Thibault Céline, Kassir Nastya, Théorêt Yves, Varin France, Litalien Catherine, Autmizguine Julie

机构信息

Clinical Pharmacology Unit, CHU Sainte-Justine, Montreal, QC, Canada.

Department of Pediatrics, CHU Sainte-Justine, Montreal, QC, Canada.

出版信息

J Popul Ther Clin Pharmacol. 2017 Aug 21;24(3):e33-344. doi: 10.22374/1710-6222.24.1.3.3.

DOI:10.22374/1710-6222.24.1.3.3
PMID:28873292
Abstract

BACKGROUND

Extended piperacillin-tazobactam (TZP) infusions have been associated with favourable outcomes. There are currently no pediatric dosing recommendations.

OBJECTIVES

To determine appropriate TZP dosing strategies in children 2 months - 6 years according to age and different minimal inhibitory concentrations (MICs).

METHODS

Age and weight were simulated for 1000 children. pharmacokinetic parameter estimates were generated using published clearance and volume of distribution data. For different dosing regimens, we estimated the probability of target attainment (PTA) over a range of MICs from 4 to 128 mg/L. The pharmacodynamic (PD) target was defined as free piperacillin concentrations above the MIC for ≥ 50% of the dosing interval. A PTA ≥ 90% was defined as optimal.

RESULTS

PTA decreased as MIC and age increased. In all age groups, standard dosing regimens (240-300 mg/kg/day, 0.5h infusions) failed to reach PTAs ≥ 90% at MICs ≥ 16 mg/L. Standard 0.5h infusions reached PTAs ≥ 90% at MICs up to 8 mg/L in infants > 2 to 6m. No 0.5h infusion reached PTAs ≥ 90% for MICs ≥ 4 mg/L in children > 6m. While none of the tested regimens were optimal at MICs > 16 mg/L in children > 6m, 100 mg/kg/dose every 6h as a 3h infusion reached PD target at MICs of 32 mg/L in infants > 2 to 6m.

CONCLUSIONS

Up to MICs of 16 mg/L, 90 mg/kg/dose every 8h as a 2h infusion in infants > 2 to 6m and 100 mg/kg/dose every 8h as a 4h infusion in children > 6m-6y achieved PTAs ≥ 90%.

摘要

背景

延长哌拉西林-他唑巴坦(TZP)输注时间与良好的治疗效果相关。目前尚无儿童用药剂量推荐。

目的

根据年龄和不同的最低抑菌浓度(MIC)确定2个月至6岁儿童合适的TZP给药策略。

方法

模拟1000名儿童的年龄和体重。使用已发表的清除率和分布容积数据生成药代动力学参数估计值。对于不同的给药方案,我们估计了在4至128mg/L的一系列MIC范围内达到目标的概率(PTA)。药效学(PD)目标定义为游离哌拉西林浓度在给药间隔的≥50%时间内高于MIC。PTA≥90%被定义为最佳。

结果

PTA随着MIC和年龄的增加而降低。在所有年龄组中,标准给药方案(240 - 300mg/kg/天,0.5小时输注)在MIC≥16mg/L时未能达到PTA≥90%。在2至6个月以上的婴儿中,标准的0.5小时输注在MIC高达8mg/L时达到PTA≥90%。在6个月以上的儿童中,没有0.5小时输注在MIC≥4mg/L时达到PTA≥90%。虽然在6个月以上的儿童中,当MIC>16mg/L时,没有一种测试方案是最佳的,但在2至6个月以上的婴儿中,每6小时100mg/kg/剂量作为3小时输注在MIC为32mg/L时达到了PD目标。

结论

在MIC高达16mg/L时,2至6个月以上的婴儿每8小时90mg/kg/剂量作为2小时输注以及6个月至6岁儿童每8小时100mg/kg/剂量作为4小时输注可使PTA≥90%。

相似文献

1
Dose-Exposure Simulation for Piperacillin-Tazobactam Dosing Strategies in Infants and Young Children.婴幼儿哌拉西林-他唑巴坦给药策略的剂量-暴露模拟
J Popul Ther Clin Pharmacol. 2017 Aug 21;24(3):e33-344. doi: 10.22374/1710-6222.24.1.3.3.
2
Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.重症患儿中延长输注哌拉西林和他唑巴坦的群体药代动力学和药效学
Antimicrob Agents Chemother. 2015 Nov 9;60(1):522-31. doi: 10.1128/AAC.02089-15. Print 2016 Jan.
3
Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.哌拉西林/他唑巴坦在危重症婴幼儿中的群体药代动力学。
Pediatr Infect Dis J. 2014 Feb;33(2):168-73. doi: 10.1097/INF.0b013e3182a743c7.
4
Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function.简化哌拉西林/他唑巴坦给药方案:针对肾功能正常和受损患者仅使用4.5克或3.375克剂量的药效学研究。
J Pharm Pract. 2017 Dec;30(6):593-599. doi: 10.1177/0897190016684453. Epub 2016 Dec 21.
5
Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.鉴定传统和延长输注哌拉西林他唑巴坦给药方案在住院患者中的最佳肾脏剂量调整。
Antimicrob Agents Chemother. 2010 Jan;54(1):460-5. doi: 10.1128/AAC.00296-09. Epub 2009 Oct 26.
6
Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.哌拉西林/他唑巴坦延长输注在成人囊性纤维化相关急性肺部感染中的药代动力学和药效学。
J Antimicrob Chemother. 2014 Jan;69(1):176-9. doi: 10.1093/jac/dkt300. Epub 2013 Jul 18.
7
Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.哌拉西林/他唑巴坦在新生儿和小婴儿群体药代动力学研究中的目标达成分析及最优抽样设计
Eur J Clin Pharmacol. 2016 Dec;72(12):1479-1488. doi: 10.1007/s00228-016-2131-0. Epub 2016 Sep 19.
8
Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.应用蒙特卡罗模拟和来自住院患者的稳态药代动力学数据比较哌拉西林/他唑巴坦间歇性和持续输注的药效动力学。
Ann Pharmacother. 2009 Nov;43(11):1747-54. doi: 10.1345/aph.1M304. Epub 2009 Oct 6.
9
Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.危重症患者行连续性肾脏替代治疗时哌拉西林他唑巴坦的群体药代动力学:在药代动力学/药效学分析中的应用。
J Antimicrob Chemother. 2014 Jan;69(1):180-9. doi: 10.1093/jac/dkt304. Epub 2013 Aug 1.
10
Piperacillin pharmacokinetics and target attainment in children with cancer and fever: Can we optimize our dosing strategy?哌拉西林在癌症合并发热儿童患者中的药代动力学和目标达成:我们能否优化我们的给药策略?
Pediatr Blood Cancer. 2019 Jun;66(6):e27654. doi: 10.1002/pbc.27654. Epub 2019 Feb 10.

引用本文的文献

1
Population Pharmacokinetics and Dose Optimization of Piperacillin in Infants and Children with Pneumonia.哌拉西林在婴幼儿肺炎患者中的群体药代动力学及剂量优化
Paediatr Drugs. 2025 Jan;27(1):91-102. doi: 10.1007/s40272-024-00664-4. Epub 2024 Nov 27.
2
Piperacillin/tazobactam treatment in children: evidence of subtherapeutic concentrations.儿童使用哌拉西林/他唑巴坦治疗:亚治疗浓度的证据。
Front Pharmacol. 2024 Jul 4;15:1254005. doi: 10.3389/fphar.2024.1254005. eCollection 2024.
3
A New Framework to Implement Model-Informed Dosing in Clinical Guidelines: Piperacillin and Amikacin as Proof of Concept.
在临床指南中实施模型指导给药的新框架:以哌拉西林和阿米卡星为例进行概念验证
Front Pharmacol. 2020 Dec 16;11:592204. doi: 10.3389/fphar.2020.592204. eCollection 2020.
4
Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children.哌拉西林-他唑巴坦延长输注在婴儿和儿童中的群体药代动力学和安全性。
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01260-19. Print 2019 Nov.